Middle East and Africa Calcineurin Inhibitors Market – Industry Trends and Forecast to 2032

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Middle East and Africa Calcineurin Inhibitors Market – Industry Trends and Forecast to 2032

  • Medical Devices
  • Published Report
  • Dec 2024
  • MEA
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 41

Middle East And Africa Calcineurin Inhibitors Market

Market Size in USD Billion

CAGR :  % Diagram

Bar chart comparing the Middle East And Africa Calcineurin Inhibitors Market size in 2024 - 320.58 and 2032 - 642.19, highlighting the projected market growth. USD 320.58 Million USD 642.19 Million 2024 2032
Diagram Forecast Period
2025 –2032
Diagram Market Size (Base Year)
USD 320.58 Million
Diagram Market Size (Forecast Year)
USD 642.19 Million
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Middle East and Africa Calcineurin Inhibitors Market, By Drugs (Tacrolimus, Cyclosporine, Pimecrolimus, Voclosporin, and Others), Route of Administeration (Oral, Topical, Parenteral, and Others), Drug Type (Branded and Generic), Application (Postoperative Immunosuppression, Atopic Dermatitis, Ulcerative Colitis, Psoriasis, Keratoconjunctivitis, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, Academic and Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) - Industry Trends & Forecast to 2032

Middle East and Africa Calcineurin Inhibitors Market

Middle East and Africa Calcineurin Inhibitors Market Analysis

Calcineurin Inhibitors (CNIs) have a significant history in the field of medicine, particularly in transplantation and immunology. The first CNI, cyclosporine, was discovered in the 1970s from a soil fungus and became a groundbreaking immunosuppressive agent after its introduction in clinical practice in the early 1980s for organ transplantation. It revolutionized transplant medicine by significantly improving graft survival rates. Following cyclosporine, tacrolimus was developed in the late 1980s, offering even more potent immunosuppressive effects. Both drugs inhibit the activity of calcineurin, an important enzyme in T-cell activation, effectively dampening the immune response. Over the years, these agents have been widely adopted for various autoimmune diseases and post-transplant management, shaping the landscape of modern immunotherapy and significantly enhancing outcomes for patients with organ transplants.

Middle East and Africa Calcineurin Inhibitors Market Size

Middle East and Africa calcineurin inhibitors market size was valued at USD 320.58 million in 2024 and is projected to reach USD 642.19 million by 2032, with a CAGR of 9.1% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.

Middle East and Africa Calcineurin Inhibitors Market Trends

“The Increasing Demand For Targeted Therapies”

One significant trend in the Middle East and Africa inhibitor market is the increasing demand for targeted therapies, particularly in oncology. As advancements in cancer research continue, inhibitors targeting specific molecular pathways have gained popularity due to their ability to precisely target cancer cells while minimizing damage to surrounding healthy tissues. This trend is driven by the growing understanding of cancer biology and the genetic mutations associated with various cancers. Targeted inhibitors, such as immune checkpoint inhibitors, are becoming central to cancer treatment regimens, offering patients more personalized and effective treatment options. Moreover, the shift towards precision medicine is driving the development of inhibitors that can address specific biomarkers, enhancing treatment outcomes. This trend is not only revolutionizing oncology but also extending to other therapeutic areas such as autoimmune diseases, cardiovascular conditions, and rare genetic disorders. As a result, the inhibitor market is expanding rapidly, with pharmaceutical companies investing heavily in research and development to bring new and innovative inhibitors to market, meeting the rising demand for more effective and tailored therapies.

Report Scope and Middle East and Africa Calcineurin Inhibitors Market Segmentation

Attributes

Middle East and Africa Calcineurin Inhibitors Market Insights

Segments Covered

  • By Drugs: Tacrolimus, Cyclosporine, Pimecrolimus, Voclosporin, Others
  • By Route of Administeration: Oral, Topical, Parenteral, Others
  • By Drug Type: Branded, Generic
  • By Application: Postoperative Immunosuppression, Atopic Dermatitis, Ulcerative Colitis, Psoriasis, Keratoconjunctivitis, Others
  • By End User: Hospitals, Specialty Clinics, Home Healthcare, Academic and research Institutes, Others
  • By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others

Region Covered

South Africa, Saudi Arabia, U.A.E., Egypt, Kuwait, Israel, and Rest Of Middle East And Africa

Key Market Players

Astellas Pharma US, Inc. (U.S.), Lupin (India), Viatris Inc. (U.S.), Glenmark Pharmaceuticals Inc. (India), Bausch Health Companies Inc. (Canada), AbbVie Inc. (U.S.), SANDOZ (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Dr. Reddy’s Laboratories Ltd. (India), Biocon (India), Apotex Inc. (Canada), and Sun Pharmaceutical Industries Ltd. (India)

Market Opportunities

  • Growing Demand For Personalized Medicine
  • Growing Geriatric Population
  • Advancements in Drug Delivery

Value Added Data Infosets

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.

Middle East and Africa Calcineurin Inhibitors Market Definition

Calcineurin inhibitors are a class of pharmaceutical agents that selectively inhibit the activity of calcineurin, a calcium-dependent serine/threonine phosphatase involved in T-cell activation and immune response regulation. These medications, including cyclosporine and tacrolimus, are primarily used in the prevention of organ transplant rejection and the treatment of autoimmune diseases due to their immunosuppressive properties. By modulating the immune system, calcineurin inhibitors help reduce inflammation and prevent the body's rejection of transplanted tissues while also posing a risk of side effects such as increased susceptibility to infections and organ toxicity. As such, the market for calcineurin inhibitors is driven by the increasing incidences of organ transplants, the prevalence of autoimmune disorders, and ongoing research into their therapeutic applications.

Middle East and Africa Calcineurin Inhibitors Market Dynamics

Drivers  

  • Rising Prevalence of Autoimmune Diseases

The rising prevalence of autoimmune diseases, such as rheumatoid arthritis, psoriasis, and other chronic inflammatory conditions, is significantly contributing to the growing demand for calcineurin inhibitors in treatment regimens. Autoimmune diseases occur when the immune system mistakenly attacks the body’s own cells, leading to inflammation and tissue damage. In conditions like rheumatoid arthritis, psoriasis, and lupus, the immune system's overactivity needs to be controlled to prevent further damage to joints, skin, and other organs. Calcineurin inhibitors, by suppressing T-cell activation and modulating immune responses, are increasingly used as part of the treatment strategy for managing these disorders. With the Middle East and Africa incidence of autoimmune diseases on the rise, fueled by factors such as genetic predisposition, environmental triggers, and lifestyle changes, the demand for effective immunosuppressive therapies like calcineurin inhibitors has escalated. These drugs play a crucial role in maintaining disease control, improving patients' quality of life, and reducing the risk of flare-ups, making them an essential part of therapeutic regimens. As the Middle East and Africa burden of autoimmune diseases continues to grow, the increased reliance on calcineurin inhibitors to manage these conditions acts as a significant driver for the expansion of the market.

For instance,

  • In June 2022, according to the article published by THE LANCLET, Autoimmune diseases affect around one in ten people, and their prevalence is steadily increasing, with varying rates across different conditions. Socioeconomic, seasonal, and regional factors point to environmental influences on disease development. Shared mechanisms among autoimmune diseases, particularly in connective tissue and endocrine disorders, drive the demand for treatments like calcineurin inhibitors, acting as a significant driver for the Middle East and Africa market.
  • In November 2022, according to the article published by NCBI, Multiple factors, including changes in diet, exposure to xenobiotics, air pollution, infections, lifestyle shifts, psychosocial stress, and climate change, are contributing to the rising prevalence of autoimmune diseases. This increase in autoimmune conditions is driving the demand for effective treatments like calcineurin inhibitors, which help manage inflammation and immune system activity, thus acting as a key driver for the Middle East and Africa market.

The increasing prevalence of autoimmune diseases, including rheumatoid arthritis, psoriasis, and lupus, is driving the demand for calcineurin inhibitors in treatment plans. These disorders occur when the immune system attacks the body’s own tissues, causing chronic inflammation. Calcineurin inhibitors help suppress immune system activity, making them valuable in managing autoimmune conditions by reducing inflammation and preventing further damage. As autoimmune diseases become more common due to factors like genetics, environmental influences, and lifestyle, the need for effective immunosuppressive treatments grows. Calcineurin inhibitors are integral to controlling symptoms, improving patients' quality of life, and preventing flare-ups. This rising prevalence of autoimmune diseases plays a key role in fueling the growth of the Middle East and Africa calcineurin inhibitors market.

  • Increasing Transplantation Procedures

The increasing number of organ transplant procedures worldwide, driven by the rising prevalence of chronic diseases such as kidney failure, liver cirrhosis, heart disease, and diabetes, is significantly boosting the demand for calcineurin inhibitors. Organ transplantation has become a critical medical solution for patients with end-stage organ failure, and effective immunosuppressive therapy is essential to prevent organ rejection following transplantation. Calcineurin inhibitors, including cyclosporine and tacrolimus, play a pivotal role in suppressing the immune system’s response, reducing the risk of transplant rejection and promoting graft survival. With advancements in transplant medicine, better surgical techniques, and improved post-transplant care, the success rates of organ transplants have increased, further driving the need for potent immunosuppressive drugs. In addition, the growing demand for organ transplants in regions with aging populations and rising incidences of organ failure continues to expand the market for calcineurin inhibitors. This surge in transplant procedures directly fuels the demand for calcineurin inhibitors, making it a key driver of market growth in the Middle East and Africa immunosuppressive drugs sector.

For instance,

  • In January 2024, according to the article published by Organ Procurement and Transplantation Network, In 2023, 46,632 organ transplants were performed, marking an 8.7% increase from 2022 and a 12.7% increase from 2021. Notably, 39,679 transplants were from deceased donors, setting a record for the eleventh consecutive year. This continued rise in transplant procedures drives the demand for calcineurin inhibitors, essential for preventing organ rejection, acting as a significant driver for the Middle East and Africa market.
  • In January 2023, according to the article published by United Network for Organ Sharing, In 2022, the United States saw 42,887 organ transplants, marking a 3.7% increase over 2021. This rise in transplant procedures reflects the growing need for effective immunosuppressive therapies to prevent organ rejection. As the number of transplants continues to grow, the demand for calcineurin inhibitors, which play a crucial role in transplant success, acts as a major driver for the Middle East and Africa market.

The rising number of organ transplants due to chronic diseases like kidney failure, liver cirrhosis, heart disease, and diabetes is driving the demand for calcineurin inhibitors. These drugs are essential for preventing organ rejection after transplants by suppressing the immune system. As transplant success rates improve with advanced techniques, the need for effective immunosuppressive treatments increases, making calcineurin inhibitors a crucial driver for market growth.

Opportunities

  • Growing Demand for Personalized Medicine

The increasing demand for personalized medicine offers a substantial opportunity for the Middle East and Africa calcineurin inhibitors market, as healthcare providers seek tailored treatment approaches that account for individual patient variability. Personalized medicine focuses on customizing drug therapies based on a patient’s genetic makeup, medical history, and specific disease characteristics. As calcineurin inhibitors are commonly used to manage autoimmune diseases and transplant rejection, their efficacy and safety vary significantly among patients. By developing personalized treatment plans that optimize the use of these immunosuppressive drugs, pharmaceutical companies can better meet the specific needs of patients, enhancing treatment outcomes and patient satisfaction.

For Instance

  • According to a study published by Elsevier B.V., the growing demand for personalized medicine stems from the recognition of significant inter-individual variation in disease processes. Emerging technologies such as DNA sequencing, proteomics, and wireless monitoring enable tailored interventions based on an individual's unique genetic, physiological, environmental, and behavioral characteristics, promising more effective treatments and prevention strategies.
  • In June 2020, a study published by MDPI highlighted that the growing demand for personalized medicine is driven by advancements in genomics and technology, enabling more precise treatments tailored to individual patients. This approach improves disease prevention, early detection, and targeted therapies, offering significant benefits in managing chronic diseases, reducing healthcare costs, and enhancing patient outcomes.

In addition, advancements in genetic profiling and biomarkers are paving the way for more precise dosing and monitoring strategies for calcineurin inhibitors. This trend aligns with the broader shift within the healthcare industry towards evidence-based and patient-centered care. As clinicians become increasingly equipped with tools to identify which patients are likely to respond best to calcineurin inhibitors, there is a growing potential to minimize adverse effects and improve efficacy. Consequently, innovations in personalized medicine can drive greater adoption of calcineurin inhibitors, positioning companies that focus on this approach for significant growth within the market.

  • Growing Geriatric Population

The growing geriatric population represents a significant opportunity for the Middle East and Africa calcineurin inhibitors market due to the increased prevalence of chronic diseases and autoimmune disorders among older adults. As individuals age, their immune systems often weaken, leading to a higher susceptibility to conditions that require immunosuppressive treatments, such as rheumatoid arthritis, lupus, and organ transplantation. This demographic shift creates a greater demand for effective therapeutic options, driving pharmaceutical companies to invest in the development and marketing of calcineurin inhibitors tailored to meet the unique needs of the elderly population.

For instance,

  • In December 2023, according to an article published by UNFPA India, the current elderly population of 153 million (aged 60 and above) is expected to reach a staggering 347 million by 2050. This increase, in turn, leads to an increased number of older patients getting affected by chronic diseases leading to the need for Calcineurin Inhibitors.

In addition, the healthcare infrastructure is evolving to better accommodate the needs of geriatric patients, including improved medication management and personalized care strategies. With advancements in medical technology and an emphasis on preventive care, there is a growing focus on optimizing treatment outcomes for older adults. By addressing the complexities associated with geriatric patients, such as polypharmacy and comorbidities, companies in the calcineurin inhibitors market have the opportunity to enhance patient adherence and overall effectiveness of treatment, thereby expanding their market presence and driving revenue growth in this lucrative segment.

Restraints/Challenges

  • Limited Efficacy for Long-Term Use of Calcineurin Inhibitors

The long-term use of calcineurin inhibitors, while essential for preventing organ rejection after transplantation, is associated with several significant complications that hinder their appeal for chronic use. Prolonged exposure to these drugs often results in nephrotoxicity, where kidney function deteriorates, increasing the risk of kidney failure. In addition, extended use has been linked to a higher incidence of cancers, particularly skin cancer and lymphomas, due to their immune-suppressing effects. These severe side effects make long-term adherence to calcineurin inhibitor treatment challenging for patients, as the risks of organ damage and cancer become more pronounced over time. For chronic conditions requiring continuous immunosuppression, such as autoimmune diseases or organ transplants, the limited long-term efficacy of calcineurin inhibitors reduces their attractiveness as a preferred treatment. This limitation in their safe and effective use over prolonged periods acts as a restraint for the Middle East and Africa market, as patients and healthcare providers seek alternatives with better long-term safety profiles.

For instance,

  • In January 2020, according to the article published by NCBI, The use of calcineurin inhibitors (CNI) can result in various toxicities, leading to both acute and chronic kidney injury, electrolyte imbalances, and adverse effects on the endocrine, nervous, and cardiovascular systems. These serious complications, especially with long-term use, limit their safety and effectiveness in chronic conditions, acting as a significant restraint on the Middle East and Africa calcineurin inhibitors market.
  • In August 2021, according to the article published by MDPI, Calcineurin inhibitors (CNIs) are linked to several side effects, including nephrotoxicity, hypertension, gingival hyperplasia, hypertrichosis, hepatotoxicity, hyperkalemia, and neurotoxicity. These adverse effects, particularly with prolonged use, limit their long-term efficacy and safety, making them less desirable for chronic treatment. This limitation in their long-term use acts as a significant restraint on the Middle East and Africa calcineurin inhibitors market.

Long-term use of calcineurin inhibitors, essential for preventing transplant rejection, leads to serious complications such as kidney damage and an increased risk of cancers, including skin cancer and lymphomas. These side effects make prolonged use challenging for patients, particularly in chronic conditions. The limited safety and effectiveness over time reduce their appeal, acting as a restraint for the Middle East and Africa market as patients and doctors seek safer alternatives.

  • Availability of Alternative Immunosuppressive Therapies

The availability of alternative immunosuppressive therapies presents a significant challenge to the Middle East and Africa calcineurin inhibitors market. The development of biologics and newer immunosuppressants with fewer side effects offers patients and healthcare providers options that are safer and more effective, particularly for long-term use. These alternatives, such as monoclonal antibodies and Janus kinase inhibitors, are designed to target specific pathways in the immune system, reducing the risk of broad immunosuppression and minimizing side effects like nephrotoxicity, hypertension, and cancer. As these therapies continue to improve in both efficacy and safety, they are increasingly preferred over traditional calcineurin inhibitors, especially in chronic conditions and organ transplants. The availability of these advanced treatments directly reduces the demand for calcineurin inhibitors, acting as a key restraint to market growth and limiting their use in the broader immunosuppressive drug market.

For Instance,

  • In August 2024, according to the article published by Cleveland Clinic, Biologics effectively manage chronic inflammation and pain, reducing the reliance on corticosteroids, which lose efficacy and increase side effects over time. Unlike non-biologic immunosuppressants, biologics are more selective, targeting specific inflammatory pathways without broadly suppressing the immune system. This improved efficacy and safety profile make biologics a preferred option, posing a restraint to the demand for calcineurin inhibitors in the market.
  • In December 2023, according to the article published by American Cancer Society, Naked monoclonal antibodies (mAbs) typically have fewer serious side effects compared to chemotherapy drugs, offering a safer alternative for immunosuppressive therapy. Their targeted action reduces overall immune suppression, minimizing adverse effects. This improved safety and efficacy make naked mAbs an attractive option, thereby limiting the demand for calcineurin inhibitors and acting as a restraint for the Middle East and Africa market.

The rise of alternative immunosuppressive therapies, such as biologics and newer drugs with fewer side effects, poses a significant challenge to the calcineurin inhibitors market. These alternatives target specific immune pathways, offering improved safety and efficacy, particularly for long-term use. As such therapies gain preference, the demand for calcineurin inhibitors decreases, acting as a restraint to market growth.

Middle East and Africa Calcineurin Inhibitors Market Scope

The market is segmented on the basis of by drugs, route of administration, drug type, application, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

  • Tacrolimus
    • By Dosage Form
      • Capsules
      • Tablets
      • Injections
      • Granules For Oral Suspension
    • By Drug Type
      • Branded
        • Prograf
        • Astagraf Xl
        • Envarsus Xr
        • Other
      • Generic
    • By Strength
      • 0.5 Mg
      • 1 Mg
      • 5 Mg
    • By Age Group
      • Adult
      • Geriatric
      • Pediatric
  • Cyclosporine
    • By Drug Type
      • Branded
        • Neoral
        • Sandimmune
        • Gengraf
        • Others
      • Generic
    • By Dosage Form
      • Capsules
      • Oral Solution
      • Tablets
      • Injection
      • Others
    • By Strength
      • 100 Mg
      • 25 Mg
      • 50 Mg
    • By Age Group
      • Adult
      • Geriatric
      • Pediatric
  • Pimecrolimus (Topical Cream)
    • By Drug Type
      • Branded
        • Elidel
        • Others
      • Generic
    • By Age Group
      • Adult
      • Geriatric
      • Pediatric
  • Voclosporin (Oral Capsule)
  • Others

Route Of Administration

  • Oral
    • Capsule
    • Tablet
    • Solution
  • Topical
  • Parenteral
  • Others

Drug Type

  • Branded
  • Generic

Application

  • Postoperative Immunosuppression
    • Branded
    • Generic
  • Atopic Dermatitiss
    • Branded
    • Generic
  • Ulcerative Colitis
    • Branded
    • Generic
  • Psoriasis
    • Branded
    • Generic
  • Keratoconjunctivitis
    • Branded
    • Generic
  • Others
    • Branded
    • Generic

End User

  • Hospitals
    • By Type
      • Public
      •  Private
    • By Level
      • Tier 3
      •  Tier 2
      •  Tier 1
  • Specialty Clinics
  •  Home Healthcare
  •  Academic And Research Institutes
  •  Others

Distribution Channel

  • Hospital Pharmacy
  •  Retail Pharmacy
  •  Online Pharmacy
  •  Others

Middle East and Africa Calcineurin Inhibitors Market Regional Analysis

The market is analyzed and market size insights and trends are provided by country, drugs, route of administration, drug type, application, end user, and distribution channel as referenced above.

The countries covered in the market are South Africa, Saudi Arabia, U.A.E., Egypt, Kuwait, Israel, and rest Of Middle East And Africa.

South Africa is expected to be the dominating & fastest growing due to due to increasing healthcare infrastructure, rising prevalence of autoimmune diseases, and growing awareness about advanced therapies.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Middle East and Africa Calcineurin Inhibitors MarketShare

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Middle East and Africa Calcineurin Inhibitors Market Leaders Operating in the Market Are:

  • Astellas Pharma US, Inc. (U.S),
  • Lupin (India)
  • Viatris Inc. (U.S.)
  • Glenmark Pharmaceuticals Inc. (India)
  • Bausch Health Companies Inc. (Canada)
  • AbbVie Inc. (U.S.)
  • SANDOZ (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Dr. Reddy’s Laboratories Ltd. (India)
  • Biocon (India)
  • Apotex Inc. (Canada)
  • Sun Pharmaceutical Industries Ltd. (India)

Latest Developments in Middle East and Africa Calcineurin Inhibitors Market

  • In November 2024, Astellas opened two advanced innovation centers in the U.S.—the West Coast Innovation Center in South San Francisco and the Life Sciences Center in Cambridge. These facilities aim to foster collaboration, scientific progress, and new treatments for Middle East and Africa patients
  • In October 2024, Viatris announced an exclusive licensing agreement with Lexicon Pharmaceuticals for sotagliflozin in all markets outside the U.S. and Europe. Approved by the FDA in 2023, the agreement expanded Viatris' cardiovascular portfolio, leveraging its Middle East and Africa infrastructure to address unmet medical needs
  • In January 2023, Viatris completed its acquisition of Oyster Point Pharma and Famy Life Sciences, forming the new Viatris Eye Care Division. Jeffrey Nau, former CEO of Oyster Point Pharma, led the division, aiming to expand their portfolio and create a Middle East and Africa eye care leader
  • In October 2024, AbbVie has reached an agreement to acquire Aliada Therapeutics .The acquisition includes Aliada's novel blood-brain barrier technology and its lead candidate, ALIA-1758, an anti-amyloid antibody for Alzheimer's treatment
  • In April 2024, AbbVie has completed its acquisition of Cerevel Therapeutics, enhancing its neuroscience portfolio. The acquisition includes Cerevel’s promising clinical-stage assets like Emraclidine for schizophrenia and Tavapadon for Parkinson's disease, strengthening AbbVie’s position in neurology and psychiatry


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 DBMR MARKET POSITION GRID

2.8 VENDOR SHARE ANALYSIS

2.9 SECONDARY SOURCES

2.1 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

5 APAC DEPRESSION SCREENING MARKET: REGULATIONS

5.1 REGULATORY AUTHORITIES IN NORTH AMERICA.

5.1.1 U.S. FOOD AND DRUG ADMINISTRATION (FDA)

5.1.2 HEALTH CANADA

5.1.3 FEDERAL COMMISSION FOR THE PROTECTION AGAINST SANITARY RISKS (COFEPRIS) - MEXICO

5.2 REGULATORY AUTHORITIES IN EUROPE.

5.2.1 GERMANY:

5.2.2 UNITED KINGDOM:

5.2.3 FRANCE:

5.2.4 ITALY:

5.2.5 SPAIN:

5.3 REGULATORY AUTHORITIES IN ASIA-PACIFIC.

5.3.1 JAPAN:

5.3.2 CHINA:

5.3.3 INDIA:

5.3.4 SOUTH KOREA:

5.3.5 AUSTRALIA:

5.4 REGULATORY AUTHORITIES IN MIDDLE EAST AND AFRICA.

5.4.1 SAUDI ARABIA:

5.4.2 UNITED ARAB EMIRATES (UAE):

5.4.3 EGYPT:

5.4.4 SOUTH AFRICA:

5.5 REGULATORY AUTHORITIES IN SOUTH AMERICA.

5.5.1 BRAZIL:

5.5.2 ARGENTINA:

5.5.3 COLOMBIA:

5.5.4 CHILE:

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING PREVALENCE OF AUTOIMMUNE DISEASES

6.1.2 INCREASING TRANSPLANTATION PROCEDURES

6.1.3 ADVANCEMENTS IN MEDICAL TECHNOLOGY

6.1.4 GOVERNMENT SUPPORT & FUNDING FOR TRANSPLANTS

6.2 RESTRAINTS

6.2.1 LIMITED EFFICACY FOR LONG-TERM USE OF CALCINEURIN INHIBITORS.

6.2.2 AVAILABILITY OF ALTERNATIVE IMMUNOSUPPRESSIVE THERAPIES.

6.3 OPPORTUNITIES

6.3.1 GROWING DEMAND FOR PERSONALIZED MEDICINE

6.3.2 GROWING GERIATRIC POPULATION

6.3.3 ADVANCEMENTS IN DRUG DELIVERY

6.4 CHALLENGES

6.4.1 COMPLEX DOSING AND MONITORING

6.4.2 HIGH COSTS

7 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY DRUGS

7.1 OVERVIEW

7.2 TACROLIMUS

7.2.1 GENERIC

7.2.2 BRANDED

7.2.2.1 PROGRAF

7.2.2.2 ASTAGRAF XL

7.2.2.3 ENVARSUS XR

7.2.2.4 OTHER

7.2.2.4.1 CAPSULES

7.2.2.4.2 TABLETS

7.2.2.4.3 INJECTIONS

7.2.2.4.4 GRANULES FOR ORAL SUSPENSION

7.2.2.4.4.1 1 MG

7.2.2.4.4.2 0.5 MG

7.2.2.4.4.3 5 MG

7.2.2.4.4.4 OTHERS

7.2.2.4.4.5 ADULT

7.2.2.4.4.6 GERIATRIC

7.2.2.4.4.7 PEDIATRIC

7.3 CYCLOSPORINE

7.3.1 GENERIC

7.3.2 BRANDED

7.3.2.1 NEORAL

7.3.2.2 SANDIMMUNE

7.3.2.3 GENGRAF

7.3.2.4 OTHERS

7.3.2.4.1 CAPSULES

7.3.2.4.2 ORAL SOLUTION

7.3.2.4.3 INJECTION

7.3.2.4.4 OTHERS

7.3.2.4.4.1 100 MG

7.3.2.4.4.2 25 MG

7.3.2.4.4.3 50 MG

7.3.2.4.4.4 OTHERS

7.3.2.4.4.5 ADULT

7.3.2.4.4.6 PEDIATRIC

7.3.2.4.4.7 GERIATRIC

7.4 PIMECROLIMUS (TOPICAL CREAM)

7.4.1 GENERIC

7.4.2 BRANDED

7.4.2.1 ADULT

7.4.2.2 GERIATRIC

7.4.2.3 PEDIATRIC

7.5 VOCLOSPORIN (ORAL CAPSULE)

7.6 OTHERS

7.6.1 GENERIC

7.6.2 BRANDED

8 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORSMARKET, BY DRUG TYPE

8.1 OVERVIEW

8.2 GENERIC

8.2.1 POSTOPERATIVE IMMUNOSUPPRESSION

8.2.2 ATOPIC DERMATITIS

8.2.3 ULCERATIVE COLITIS

8.2.4 PSORIASIS

8.2.5 KERATOCONJUNCTIVITIS

8.2.6 OTHERS

8.3 BRANDED

8.3.1 POSTOPERATIVE IMMUNOSUPPRESSION

8.3.2 ATOPIC DERMATITIS

8.3.3 ULCERATIVE COLITIS

8.3.4 PSORIASIS

8.3.5 KERATOCONJUNCTIVITIS

8.3.6 OTHERS

9 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 POSTOPERATIVE IMMUNOSUPPRESSION

9.3 ATOPIC DERMATITIS

9.4 ULCERATIVE COLITIS

9.5 PSORIASIS

9.6 KERATOCONJUNCTIVITIS

9.7 OTHERS

10 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

10.1 OVERVIEW

10.2 ORAL

10.2.1 CAPSULE

10.2.2 TABLET

10.2.3 SOLUTION

10.3 TOPICAL

10.4 PARENTERAL

10.5 OTHERS

11 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 SPECIALTY CLINICS

11.4 HOME HEALTHCARE

11.5 ACADEMIC AND RESEARCH INSTITUTES

11.6 OTHERS

12 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORSMARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 HOSPITAL PHARMACY

12.3 RETAIL PHARMACY

12.4 ONLINE PHARMACY

12.5 OTHERS

13 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITOR MARKET, BY REGION

13.1 MIDDLE EAST AND AFRICA

14 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

15 SWOT ANALYSIS

16 COMPANY PROFILES

16.1 ASTELLAS PHARMA US, INC.

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENT

16.2 CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENT

16.3 LUPIN

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENT

16.4 HUADONG MEDICINE CO.,LTD

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENT

16.5 VIATRIS INC.

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 COMPANY SHARE ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 RECENT DEVELOPMENT

16.6 APOTEX INC.

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVELOPMENT

16.7 ABBVIE INC

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENT

16.8 ACCORD HEALTHCARE US.

16.8.1 COMPANY SNAPSHOT

16.8.2 PRODUCT PORTFOLIO

16.8.3 RECENT DEVELOPMENT

16.9 ACTIZAPHARMA

16.9.1 COMPANY SNAPSHOT

16.9.2 PRODUCT PORTFOLIO

16.9.3 RECENT DEVELOPMENT

16.1 ADVACARE PHARMA

16.10.1 COMPANY SNAPSHOT

16.10.2 PRODUCT PORTFOLIO

16.10.3 RECENT DEVELOPMENT

16.11 BIOCON

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENT

16.12 BAUSCH HEALTH COMPANIES INC.

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENT

16.13 CONCORD BIOTECH

16.13.1 COMPANY SNAPSHOT

16.13.2 REVENUE ANALYSIS

16.13.3 PRODUCT PORTFOLIO

16.13.4 RECENT DEVELOPMENT

16.14 DR. REDDY’S LABORATORIES

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENT

16.15 GLENMARK PHARMACEUTICALS INC

16.15.1 COMPANY SNAPSHOT

16.15.2 REVENUE ANALYSIS

16.15.3 PRODUCT PORTFOLIO

16.15.4 RECENT DEVELOPMENT

16.16 LEO PHARMA INC.

16.16.1 COMPANY SNAPSHOT

16.16.2 PRODUCT PORTFOLIO

16.16.3 RECENT DEVELOPMENT

16.17 LIPELLA PHARMACEUTICALS, INC.

16.17.1 COMPANY SNAPSHOT

16.17.2 REVENUE ANALYSIS

16.17.3 PRODUCT PORTFOLIO

16.17.4 RECENT DEVELOPMENT

16.18 NOVARTIS AG

16.18.1 COMPANY SNAPSHOT

16.18.2 REVENUE ANALYSIS

16.18.3 PRODUCT PORTFOLIO

16.18.4 RECENT DEVELOPMENT

16.19 NOVALIQ GMBH

16.19.1 COMPANY SNAPSHOT

16.19.2 PRODUCT PORTFOLIO

16.19.3 RECENT DEVELOPMENT

16.2 PANACEA BIOTEC

16.20.1 COMPANY SNAPSHOT

16.20.2 REVENUE ANALYSIS

16.20.3 PRODUCT PORTFOLIO

16.20.4 RECENT DEVELOPMENT

16.21 PADAGIS

16.21.1 COMPANY SNAPSHOT

16.21.2 PRODUCT PORTFOLIO

16.21.3 RECENT DEVELOPMENT

16.22 RPG LIFE SCIENCES LIMITED

16.22.1 COMPANY SNAPSHOT

16.22.2 REVENUE ANALYSIS

16.22.3 PRODUCT PORTFOLIO

16.22.4 RECENT DEVELOPMENT

16.23 VELOXIS PHARMACEUTICALS, INC.

16.23.1 COMPANY SNAPSHOT

16.23.2 REVENUE ANALYSIS

16.23.3 PRODUCT PORTFOLIO

16.23.4 RECENT DEVELOPMENT

16.24 ZHAOKE OPHTHALMOLOGY LIMITED

16.24.1 COMPANY SNAPSHOT

16.24.2 REVENUE ANALYSIS

16.24.3 PRODUCT PORTFOLIO

16.24.4 RECENT DEVELOPMENT

16.25 ZAMBON COMPANY S.P.A.

16.25.1 COMPANY SNAPSHOT

16.25.2 PRODUCT PORTFOLIO

16.25.3 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

List of Table

TABLE 1 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 2 MIDDLE EAST AND AFRICA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 3 MIDDLE EAST AND AFRICA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 9 MIDDLE EAST AND AFRICA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)

TABLE 13 MIDDLE EAST AND AFRICA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA VOCLOSPORIN (ORAL CAPSULE) IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA OTHERS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA OTHERS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA GENERIC IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA BRANDED IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA POSTOPERATIVE IMMUNOSUPPRESSION IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA ATOPIC DERMATITIS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA ULCERATIVE COLITIS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA PSORIASIS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA KERATOCONJUNCTIVITIS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA OTHERS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA ORAL IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA ORAL IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA TOPICAL IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA PARENTRAL IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA OTHERS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY LEVEL, 2018-2032 (USD MILLION)

TABLE 42 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 43 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 44 MIDDLE EAST AND AFRICA ACADEMIC AND RESEARCH INSTITUTES IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 45 MIDDLE EAST AND AFRICA OTHERS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 46 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 47 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032(USD MILLION)

TABLE 48 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 49 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 50 MIDDLE EAST AND AFRICA OTHERS IN CALCINEURIN INHIBITORS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 51 MIDDLE EAST AND AFRICA CALCENURIN INHIBITORS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)

TABLE 52 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 53 MIDDLE EAST AND AFRICA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 54 MIDDLE EAST AND AFRICA BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 55 MIDDLE EAST AND AFRICA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)

TABLE 56 MIDDLE EAST AND AFRICA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)

TABLE 57 MIDDLE EAST AND AFRICA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 58 MIDDLE EAST AND AFRICA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 59 MIDDLE EAST AND AFRICA BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 60 MIDDLE EAST AND AFRICA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)

TABLE 61 MIDDLE EAST AND AFRICA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)

TABLE 62 MIDDLE EAST AND AFRICA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 63 MIDDLE EAST AND AFRICA PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 64 MIDDLE EAST AND AFRICA PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 65 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 66 MIDDLE EAST AND AFRICA ORAL IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 67 MIDDLE EAST AND AFRICA OTHERS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 68 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 69 MIDDLE EAST AND AFRICA GENERIC IN CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 70 MIDDLE EAST AND AFRICA BRANDED IN CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 71 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 72 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 73 MIDDLE EAST AND AFRICA HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 74 MIDDLE EAST AND AFRICA HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY LEVEL, 2018-2032 (USD MILLION)

TABLE 75 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 76 SOUTH AFRICA CALCINEURIN INHIBITORS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 77 SOUTH AFRICA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 78 SOUTH AFRICA BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 79 SOUTH AFRICA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)

TABLE 80 SOUTH AFRICA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)

TABLE 81 SOUTH AFRICA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 82 SOUTH AFRICA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 83 SOUTH AFRICA BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 84 SOUTH AFRICA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)

TABLE 85 SOUTH AFRICA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)

TABLE 86 SOUTH AFRICA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 87 SOUTH AFRICA PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 88 SOUTH AFRICA PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 89 SOUTH AFRICA CALCINEURIN INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 90 SOUTH AFRICA ORAL IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 91 SOUTH AFRICA OTHERS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 92 SOUTH AFRICA CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 93 SOUTH AFRICA GENERIC IN CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 94 SOUTH AFRICA BRANDED IN CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 95 SOUTH AFRICA CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 96 SOUTH AFRICA CALCINEURIN INHIBITORS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 97 SOUTH AFRICA HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 98 SOUTH AFRICA HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY LEVEL, 2018-2032 (USD MILLION)

TABLE 99 SOUTH AFRICA CALCINEURIN INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 100 SAUDI ARABIA CALCINEURIN INHIBITORS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 101 SAUDI ARABIA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 102 SAUDI ARABIA BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 103 SAUDI ARABIA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)

TABLE 104 SAUDI ARABIA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)

TABLE 105 SAUDI ARABIA TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 106 SAUDI ARABIA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 107 SAUDI ARABIA BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 108 SAUDI ARABIA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)

TABLE 109 SAUDI ARABIA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)

TABLE 110 SAUDI ARABIA CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 111 SAUDI ARABIA PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 112 SAUDI ARABIA PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 113 SAUDI ARABIA CALCINEURIN INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 114 SAUDI ARABIA ORAL IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 115 SAUDI ARABIA OTHERS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 116 SAUDI ARABIA CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 117 SAUDI ARABIA GENERIC IN CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 118 SAUDI ARABIA BRANDED IN CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 119 SAUDI ARABIA CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 120 SAUDI ARABIA CALCINEURIN INHIBITORS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 121 SAUDI ARABIA HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 122 SAUDI ARABIA HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY LEVEL, 2018-2032 (USD MILLION)

TABLE 123 SAUDI ARABIA CALCINEURIN INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 124 U.A.E CALCINEURIN INHIBITORS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 125 U.A.E TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 126 U.A.E BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 127 U.A.E TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)

TABLE 128 U.A.E TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)

TABLE 129 U.A.E TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 130 U.A.E CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 131 U.A.E BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 132 U.A.E CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)

TABLE 133 U.A.E CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)

TABLE 134 U.A.E CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 135 U.A.E PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 136 U.A.E PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 137 U.A.E CALCINEURIN INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 138 U.A.E ORAL IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 139 U.A.E OTHERS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 140 U.A.E CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 141 U.A.E GENERIC IN CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 142 U.A.E BRANDED IN CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 143 U.A.E CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 144 U.A.E CALCINEURIN INHIBITORS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 145 U.A.E HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 146 U.A.E HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY LEVEL, 2018-2032 (USD MILLION)

TABLE 147 U.A.E CALCINEURIN INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 148 EGYPT CALCINEURIN INHIBITORS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 149 EGYPT TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 150 EGYPT BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 151 EGYPT TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)

TABLE 152 EGYPT TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)

TABLE 153 EGYPT TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 154 EGYPT CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 155 EGYPT BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 156 EGYPT CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)

TABLE 157 EGYPT CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)

TABLE 158 EGYPT CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 159 EGYPT PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 160 EGYPT PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 161 EGYPT CALCINEURIN INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 162 EGYPT ORAL IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 163 EGYPT OTHERS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 164 EGYPT CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 165 EGYPT GENERIC IN CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 166 EGYPT BRANDED IN CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 167 EGYPT CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 168 EGYPT CALCINEURIN INHIBITORS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 169 EGYPT HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 170 EGYPT HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY LEVEL, 2018-2032 (USD MILLION)

TABLE 171 EGYPT CALCINEURIN INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 172 ISRAEL CALCINEURIN INHIBITORS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 173 ISRAEL TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 174 ISRAEL BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 175 ISRAEL TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)

TABLE 176 ISRAEL TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)

TABLE 177 ISRAEL TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 178 ISRAEL CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 179 ISRAEL BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 180 ISRAEL CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)

TABLE 181 ISRAEL CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)

TABLE 182 ISRAEL CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 183 ISRAEL PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 184 ISRAEL PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 185 ISRAEL CALCINEURIN INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 186 ISRAEL ORAL IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 187 ISRAEL OTHERS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 188 ISRAEL CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 189 ISRAEL GENERIC IN CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 190 ISRAEL BRANDED IN CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 191 ISRAEL CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 192 ISRAEL CALCINEURIN INHIBITORS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 193 ISRAEL HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 194 ISRAEL HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY LEVEL, 2018-2032 (USD MILLION)

TABLE 195 ISRAEL CALCINEURIN INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 196 KUWAIT CALCINEURIN INHIBITORS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

TABLE 197 KUWAIT TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 198 KUWAIT BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 199 KUWAIT TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)

TABLE 200 KUWAIT TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)

TABLE 201 KUWAIT TACROLIMUS IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 202 KUWAIT CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 203 KUWAIT BRANDED IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 204 KUWAIT CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY DOSAGE FORM, 2018-2032 (USD MILLION)

TABLE 205 KUWAIT CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY STRENGTH, 2018-2032 (USD MILLION)

TABLE 206 KUWAIT CYCLOSPORINE IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 207 KUWAIT PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 208 KUWAIT PIMECROLIMUS (TOPICAL CREAM) IN CALCINEURIN INHIBITORS MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)

TABLE 209 KUWAIT CALCINEURIN INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 210 KUWAIT ORAL IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 211 KUWAIT OTHERS IN CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 212 KUWAIT CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 213 KUWAIT GENERIC IN CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 214 KUWAIT BRANDED IN CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 215 KUWAIT CALCINEURIN INHIBITORS MARKET, BY APPLICATION, 2018-2032 (USD MILLION)

TABLE 216 KUWAIT CALCINEURIN INHIBITORS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 217 KUWAIT HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 218 KUWAIT HOSPITALS IN CALCINEURIN INHIBITORS MARKET, BY LEVEL, 2018-2032 (USD MILLION)

TABLE 219 KUWAIT CALCINEURIN INHIBITORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 220 REST OF MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY DRUGS, 2018-2032 (USD MILLION)

List of Figure

FIGURE 1 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: SEGMENTATION

FIGURE 10 EXECUTIVE SUMMARY

FIGURE 11 STRATEGIC DECISIONS

FIGURE 12 FIVE SEGMENTS COMPRISE THE MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY DRUGS

FIGURE 13 RISING PREVALENCE OF AUTOIMMUNE DISEASES IS DRIVING THE GROWTH OF THE MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET FROM 2025 TO 2032

FIGURE 14 THE TACROLIMUS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET IN 2025 AND 2032

FIGURE 15 DROC ANALYSIS

FIGURE 16 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY DRUGS, 2024

FIGURE 17 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY DRUGS, 2025-2032 (USD MILLION)

FIGURE 18 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY DRUGS, CAGR (2025-2032)

FIGURE 19 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY DRUGS, LIFELINE CURVE

FIGURE 20 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY DRUG TYPE,2024

FIGURE 21 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY DRUG TYPE, 2025-2032 (USD MILLION)

FIGURE 22 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY DRUG TYPE, CAGR (2025-2032)

FIGURE 23 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 24 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY APPLICATION, 2024

FIGURE 25 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY APPLICATION, 2025-2032 (USD MILLION)

FIGURE 26 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY APPLICATION, CAGR (2025-2032)

FIGURE 27 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 28 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY ROUTE OF ADMINISTRATION, 2024

FIGURE 29 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)

FIGURE 30 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2025-2032)

FIGURE 31 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 32 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY END USER, 2024

FIGURE 33 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY END USER, 2025-2032 (USD MILLION)

FIGURE 34 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY END USER, CAGR (2025-2032)

FIGURE 35 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY END USER, LIFELINE CURVE

FIGURE 36 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY DISTRIBUTION CHANNEL, 2024

FIGURE 37 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)

FIGURE 38 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)

FIGURE 39 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 40 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITOR MARKET: SNAPSHOT (2024)

FIGURE 41 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET: COMPANY SHARE 2024 (%)

View Detailed Information Right Arrow

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The market is segmented based on Middle East and Africa Calcineurin Inhibitors Market, By Drugs (Tacrolimus, Cyclosporine, Pimecrolimus, Voclosporin, and Others), Route of Administeration (Oral, Topical, Parenteral, and Others), Drug Type (Branded and Generic), Application (Postoperative Immunosuppression, Atopic Dermatitis, Ulcerative Colitis, Psoriasis, Keratoconjunctivitis, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, Academic and Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) - Industry Trends & Forecast to 2032 .
The Middle East and Africa Calcineurin Inhibitors Market size was valued at USD 320.58 USD Million in 2024.
The Middle East and Africa Calcineurin Inhibitors Market is projected to grow at a CAGR of 9.1% during the forecast period of 2025 to 2032.
Testimonial